We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Sandra and Edward Meyer Cancer Center

Warning message

The subscription service is currently unavailable. Please try again later.

You are here

News

Panoply of new agents, complete remission rates mark ‘special day’ in myeloma

Friday, April 15, 2016

Ruben Niesvizky, MD

In this video on Healio.com, Ruben Niesvizky, M.D., director of the Multiple Myeloma Center at Weill Cornell Medicine in New York, discusses the “privilege” of caring for patients with myeloma in an era of therapeutic milestones.

“We’re starting to talk about complete remission in a much deeper context,” he said. “The ability to achieve complete remission to a minimal residual disease-negative state has allowed patients to live longer and have better quality of life.”

Niesvizky discusses three-agent combinations of proteasome inhibitors, immunomodulators and corticosteroids and the “revolution” in agents available for relapsed and refractory disease, detailing therapeutic scenarios and their respective responses.

He also outlines the distinct treatment phases involved in today’s treatment paradigms, highlighting the “major impact” seen using a combination of carfilzomib (Kyprolis, Onyx Pharmaceuticals), lenalidomide (Revlimid; Celgene) and dexamethasone for induction.

He goes on to highlight the progress in using immune-based strategies, including monoclonal antibodies either alone or in combination with other therapies, and details populations in which the approaches show promise.